Archive · 16 Sep 2025
New Drug Shows Promise for Fatty Liver Disease
Scientists are testing a new medicine, ION224, to help with a liver problem called MASH, which is similar to the problem Dan Marino has.
MASH happens when too much fat builds up in the liver.
The drug works by blocking an enzyme, reducing fat and inflammation.
In a study, the drug showed good results, even when people did not lose weight.
If it continues to show positive results, this medicine may stop or reverse damage before it becomes serious.
Researchers identified ION224 as a potential treatment for MASH.
The drug targets the DGAT2 enzyme to reduce fat buildup and inflammation.
A Phase IIb clinical trial involved 160 adults with MASH.
At the highest dose, 60% showed improvements in liver health.
The drug showed no serious side effects.
- Who
- Researchers at UC San Diego School of Medicine
- What
- Identified a drug that may treat MASH
- When
- Study published August 23, 2025
- Where
- UC San Diego School of Medicine; multicenter trial in the United States
- Why
- To combat MASH and prevent liver damage
- Drug Name
- ION224
- Target
- DGAT2 enzyme
- Disease
- Metabolic dysfunction-associated steatohepatitis (MASH)
- Study Publisher
- The Lancet
- Study Findings
- 60% of participants showed improvement
- Study Stage
- Phase IIb
- Participants
- 160 adults
- Potential Outcome
- Halt or reverse liver damage
